Incyte Corporation vs Teladoc Health Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Teladoc Health Inc trades at $9.7 (market cap $1.74B). The key difference: Incyte Corporation is far larger — about 13.3× Teladoc Health Inc's market cap. Which is the better fit depends on your goals.
| INCY | TDOC | |
|---|---|---|
Market Cap | $23.11B | $1.74B |
Sector | Health | Health |
52-Week High | $118.52 | $9.72 |
52-Week Low | $67.38 | $4.47 |
Enterprise Value | $19.13B | $2.03B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →